Companies Amarin Corp PLC\UK
Amarin Corp PLC\UK (AMRN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Amarin Corp PLC\UK’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers50th pct.Of 16 peer CEOs
CEO pay, last three years
- $2,448,149FY2023
- $3,277,385FY2024
- $3,540,366FY2025
CEO total pay was $3,540,366 in fiscal 2025, up from $3,277,385 in fiscal 2024.
FY2025: salary $725,667 · bonus $332,326 · stock awards $1,391,250 · option awards $493,975
Executives and directors
Aaron Berg · CEODavid Keenan · COOPeter Fishman · CFOJonathan Provoost · General CounselSteven Ketchum · EVPDiane E. Sullivan · Independent DirectorKeith L. Horn · Independent DirectorLouis Sterling III · Independent DirectorMark DiPaolo · Former director (through FY2025)Michael Torok · Independent DirectorOdysseas Kostas · Chair of the BoardOliver O'Connor · Former director (through FY2025)Patrice Bonfiglio · Independent DirectorPaul Cohen · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at Amarin Corp PLC\UK in fiscal 2025?
As disclosed, Aaron Berg (President and Chief Executive Officer) was the highest-paid executive at Amarin Corp PLC\UK in fiscal 2025, with total compensation of $3,540,366.
How does Amarin Corp PLC\UK's chief executive pay compare to its disclosed peer group?
As disclosed, Aaron Berg's total compensation ranked at the 50th percentile of Amarin Corp PLC\UK's disclosed peer group.
What is Amarin Corp PLC\UK's CEO-to-median employee pay ratio?
As disclosed, Amarin Corp PLC\UK's CEO-to-median employee pay ratio was 11:1.
How did shareholders vote on Amarin Corp PLC\UK's executive compensation?
As disclosed, 51.9% of shareholders supported Amarin Corp PLC\UK's executive compensation in the latest say-on-pay vote.
How much does Amarin Corp PLC\UK spend in total on board compensation for fiscal 2025?
As disclosed, Amarin Corp PLC\UK reported total board compensation of $485,161 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Aaron Berg | $725,667 | $332,326 | $1,391,250 | $493,975 | $588,300 | $0 | $8,848 | $3,540,366 |
| President and Chief Executive Officer | ||||||||
| Steven Ketchum | 687,490 | 429,096 | 91,462 | 339,564 | 364,610 | 0 | 8,848 | 1,921,070 |
| Executive Vice President, President of Research and Development and Chief Scientific Officer | ||||||||
| David Keenan | 452,685 | 357,775 | 91,462 | 339,564 | 301,341 | 0 | 73,478 | 1,616,306 |
| Executive Vice President, Chief Operating Officer | ||||||||
| Jonathan Provoost | 484,181 | 186,000 | 91,462 | 339,564 | 257,085 | 0 | 3,941 | 1,362,233 |
| Executive Vice President, Chief Legal & Compliance Officer and Secretary | ||||||||
| Peter Fishman | 400,000 | 173,750 | 60,686 | 225,295 | 169,300 | 0 | 7,939 | 1,036,970 |
| Senior Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Aaron Berg | $3,540,366 | $3,277,385 | $2,448,149 | ↑ +262,981 |
| Steven Ketchum | 1,921,070 | 1,732,827 | 2,350,567 | ↑ +188,243 |
| David Keenan | 1,616,306 | — | — | — |
| Jonathan Provoost | 1,362,233 | 701,819 | 659,264 | ↑ +660,414 |
| Peter Fishman | 1,036,970 | 606,000 | — | ↑ +430,970 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Executive compensation should be directly linked both to continuous improvements in corporate performance (so-called “ pay for performance ”) and accomplishment of strategic objectives, and to align our executives’ interests with those of our shareholders by rewarding short-term and long-term performance and tying compensation to increases in shareholder value.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jonathan Provoost | OPTION | 2025-01-10 | — | — | 663,860 | — | $339,564 |
| Peter Fishman | OPTION | 2025-01-10 | — | — | 440,460 | — | 225,295 |
| Steven Ketchum | OPTION | 2025-01-10 | — | — | 663,860 | — | 339,564 |
| Aaron Berg | OPTION | 2025-06-26 | — | — | 750,000 | — | 493,975 |
| David Keenan | OPTION | 2025-01-10 | — | — | 663,860 | — | 339,564 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jonathan Provoost | $0 | $0 | $339,564 | 0.0% |
| Peter Fishman | 0 | 0 | 225,295 | 0.0% |
| Steven Ketchum | 0 | 0 | 339,564 | 0.0% |
| Aaron Berg | 0 | 0 | 493,975 | 0.0% |
| David Keenan | 0 | 0 | 339,564 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Aaron Berg | Option | 8,220 | 3.66 | — |
| Steven Ketchum | Option | 8,220 | 3.66 | — |
| David Keenan | Option | 12,500 | 1.45 | — |
| Aaron Berg | Option | 84,240 | 1.8 | — |
| Steven Ketchum | Option | 84,240 | 1.8 | — |
| David Keenan | Option | 84,260 | 1.8 | — |
| Aaron Berg | Option | 174,160 | 1.21 | — |
| David Keenan | Option | 174,160 | 1.21 | — |
| Steven Ketchum | Option | 174,160 | 1.21 | — |
| Jonathan Provoost | Option | 400,000 | 0.75 | — |
| Peter Fishman | Option | 440,460 | 0.62 | — |
| David Keenan | Option | 663,860 | 0.62 | — |
| Steven Ketchum | Option | 663,860 | 0.62 | — |
| Jonathan Provoost | Option | 663,860 | 0.62 | — |
| Aaron Berg | Option | 750,000 | 0.8 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Odysseas KostasIndependent · Board Chair · Nominating and Corporate Governance | $73,577 | $0 | $0 | — | $0 | $73,577 |
| Keith L. HornIndependent · Audit (Chair) · Remuneration · Compensation | 71,903 | 0 | 0 | — | 0 | 71,903 |
| Diane E. SullivanIndependent · Audit · Remuneration (Chair) · Compensation (Chair) | 68,842 | 0 | 0 | — | 0 | 68,842 |
| Louis Sterling IIIIndependent · Audit · Nominating and Corporate Governance (Chair) | 67,532 | 0 | 0 | — | 0 | 67,532 |
| Patrice BonfiglioIndependent · Audit · Remuneration · Compensation | 63,089 | 0 | 0 | — | 0 | 63,089 |
| Paul CohenIndependent · Nominating and Corporate Governance · Not standing for re-election · Departed during FY | 54,711 | 0 | 0 | — | 0 | 54,711 |
| Oliver O'ConnorNominating and Corporate Governance · Not standing for re-election · Departed during FY | 32,883 | 0 | 0 | — | 0 | 32,883 |
| Michael TorokIndependent · Remuneration · Compensation · Newly elected | 31,189 | 0 | 0 | — | 0 | 31,189 |
| Mark DiPaoloNot standing for re-election · Departed during FY | 21,435 | 0 | 0 | — | 0 | 21,435 |
| Aaron D. BergEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $62,500 |
|---|---|
| Annual equity retainer | $175,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 11,000 |
| Stock ownership guideline | Director Stock Ownership Guidelines 73 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $485,161 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $485,161 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Amarin Corp PLC\UK as a peer
Companies that benchmark against AMRN
2 companies name AMRN as a compensation peer
- Innoviva, Inc.INVAFY2025
- Vanda Pharmaceuticals Inc.VNDAFY2025
Each company listed discloses AMRN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AMRN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ESPR Esperion Therapeutics, Inc.CHRS Coherus BioSciences, Inc.RVNC Revance Therapeutics Inc.TVTX Travere Therapeutics, Inc.VNDA Vanda Pharmaceuticals Inc.EOLS Evolus, Inc.HRTX Heron Therapeutics, Inc.KPTI Karyopharm Therapeutics, Inc.PBYI Puma Biotechnology, Inc.COLL Collegium Pharmaceutical, Inc.IRWD Ironwood Pharmaceuticals, Inc.RIGL Rigel Pharmaceuticals Inc.HROW Harrow, Inc.INVA Innoviva, Inc.MGNX MacroGenics, Inc.XERS Xeris Biopharma Holdings Inc.
Peer reciprocity
The companies Amarin Corp PLC\UK names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Harrow, Inc. | 2025 | Mark Baum | $754,910 | $22,294,873 | $0 | $542,491 | $23,606,274 |
| 2 | Revance Therapeutics Inc. | 2023 | Mark Foley | 720,000 | 8,810,731 | 0 | 522,720 | 10,068,915 |
| 3 | Travere Therapeutics, Inc. | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 4 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 5 | Innoviva, Inc. | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 6 | Xeris Biopharma Holdings Inc. | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 7 | Rigel Pharmaceuticals Inc. | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 8 | Vanda Pharmaceuticals Inc. | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 9 | Amarin Corp PLC\UK | 2025 | Aaron Berg | 725,667 | 1,391,250 | 493,975 | 588,300 | 3,540,366 |
| 10 | Esperion Therapeutics, Inc. | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 11 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 12 | Puma Biotechnology, Inc. | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 13 | Coherus BioSciences, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 14 | Karyopharm Therapeutics, Inc. | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 15 | MacroGenics, Inc. | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 16 | Ironwood Pharmaceuticals, Inc. | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 17 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Amarin Corp PLC\UK | 107.75% | Options 75 · RSU 25 | not disclosed | Pearl Meyer |
| Coherus BioSciences, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Esperion Therapeutics, Inc. | 110% | not disclosed | not disclosed | not disclosed |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Harrow, Inc. | 100% | not disclosed | No | Mercer, Inc. |
| Heron Therapeutics, Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Innoviva, Inc. | 105% | not disclosed | not disclosed | Meridian |
| Ironwood Pharmaceuticals, Inc. | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Karyopharm Therapeutics, Inc. | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| MacroGenics, Inc. | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Puma Biotechnology, Inc. | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Revance Therapeutics Inc. | 96.8% | PSU 100 | No | FW Cook |
| Rigel Pharmaceuticals Inc. | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Travere Therapeutics, Inc. | 150% | not disclosed | No | Aon |
| Vanda Pharmaceuticals Inc. | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| Xeris Biopharma Holdings Inc. | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-13 | 87,198,317 | 80,807,440 | 17,509,840 | 51.9% | Passed |
| 2025 | 2025-05-13 | 88,817,073 | 36,111,698 | 6,716,644 | 71.09% | Passed |
| 2024 | 2024-04-18 | 111,449,588 | 28,688,121 | 3,628,098 | 79.53% | Passed |
| 2023 | 2023-07-21 | 116,866,034 | 35,233,586 | 4,934,471 | 76.84% | Passed |
| 2022 | 2022-06-27 | 85,564,198 | 45,523,022 | 53,634,850 | 65.27% | Passed |
| 2021 | 2021-06-14 | 102,483,113 | 38,858,776 | 1,587,322 | 72.51% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-13 | 51.9%a |
| 2025 | 2025-05-13 | 71.09%b |
| 2024 | 2024-04-18 | 79.53%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
c. Approved under the standard stated in the filing — “As a result, abstentions and broker non-votes will have no effect on the vote outcome.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 11 : 1 |
|---|---|
| CEO total compensation | $3,540,366 |
| Median employee compensation | $326,639 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Oliver O'Connor | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Keith L. Horn | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-04-18 | — | 5,866 | — | — | 7 insiders, 7 accrual rows | ||
| Diane E. Sullivan | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Louis Sterling III | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Patrice Bonfiglio | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Patrice Bonfiglio | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Oliver O'Connor | Director | 2026-04-18 | D | 438 | 15 | 6,561 | Common | Form 4 ↗ |
| Keith L. Horn | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Kostas D. Odysseas | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Kostas D. Odysseas | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Paul Cohen | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Louis Sterling III | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Paul Cohen | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | D | 3,197 | 16 | 52,271 | Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | A | 6,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | A | 6,250 | — | — | Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | D | 1,264 | 16 | 20,148 | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | A | 2,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | D | 1,887 | 16 | 30,079 | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | D | 1,926 | 16 | 30,700 | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | A | 2,447 | — | — | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | D | 1,206 | 16 | 19,224 | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-01 | — | 313 | — | — | 1 insider, 1 accrual row | ||
| Peter Fishman | SVP, CFO | 2026-08-01 | D | 155 | 14 | 2,210 | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-08-01 | A | 313 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 39 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Oliver O'Connor | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Keith L. Horn | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Louis Sterling III | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Paul Cohen | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrice Bonfiglio | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Patrice Bonfiglio | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Oliver O'Connor | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Oliver O'Connor | Director | 2026-04-18 | D | 438 | 15 | 6,561 | Common | Form 4 ↗ |
| Keith L. Horn | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Diane E. Sullivan | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Kostas D. Odysseas | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Kostas D. Odysseas | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Louis Sterling III | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Paul Cohen | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Patrice Bonfiglio | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith L. Horn | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kostas D. Odysseas | Director | 2026-04-18 | A | 838 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Louis Sterling III | Director | 2026-04-18 | A | 838 | — | — | Common | Form 4 ↗ |
| Paul Cohen | Director | 2026-04-18 | D | 403 | 15 | 6,037 | Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | D | 3,197 | 16 | 52,271 | Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | A | 6,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Berg | President and CEO | 2026-06-26 | A | 6,250 | — | — | Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | D | 1,264 | 16 | 20,148 | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | A | 2,447 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Provoost | EVP, Chief Legal Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | D | 1,887 | 16 | 30,079 | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | D | 1,926 | 16 | 30,700 | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | A | 3,688 | — | — | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | A | 2,447 | — | — | Common | Form 4 ↗ |
| David Keenan | EVP, Chief Operating Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-07-01 | D | 1,206 | 16 | 19,224 | Common | Form 4 ↗ |
| Steven Ketchum | EVP, Chief Scientific Officer | 2026-07-01 | A | 3,688 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-08-01 | A | 313 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-08-01 | D | 155 | 14 | 2,210 | Common | Form 4 ↗ |
| Peter Fishman | SVP, CFO | 2026-08-01 | A | 313 | — | — | Common | Form 4 ↗ |
Sources (85 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Aaron Berg. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table” · page 52. As printed: 3,540,366. View filing ↗
- Section 01, Steven Ketchum. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,921,070. View filing ↗
- Section 01, David Keenan. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,616,306. View filing ↗
- Section 01, Jonathan Provoost. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,362,233. View filing ↗
- Section 01, Peter Fishman. DEF 14A, filed 2026-04-10. Section “2025 Summary Compensation Table”. As printed: 1,036,970. View filing ↗
- Section 03, Jonathan Provoost OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Peter Fishman OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Steven Ketchum OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Berg OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. View filing ↗
- Section 03, David Keenan OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards Tables for the Fiscal Year Ended December 31, 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-10. Section “CEO Pay Ratio”. As printed: 11 : 1. View filing ↗
- Section 08, Odysseas Kostas. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 73,577. View filing ↗
- Section 08, Keith L. Horn. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 71,903. View filing ↗
- Section 08, Diane E. Sullivan. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 68,842. View filing ↗
- Section 08, Louis Sterling III. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 67,532. View filing ↗
- Section 08, Patrice Bonfiglio. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 63,089. View filing ↗
- Section 08, Paul Cohen. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 54,711. View filing ↗
- Section 08, Oliver O'Connor. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 32,883. View filing ↗
- Section 08, Michael Torok. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 31,189. View filing ↗
- Section 08, Mark DiPaolo. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 21,435. View filing ↗
- Section 08, Aaron D. Berg. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Oliver O'Connor 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith L. Horn 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Louis Sterling III 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Cohen 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrice Bonfiglio 2026-04-18. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrice Bonfiglio 2026-04-18. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Oliver O'Connor 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Oliver O'Connor 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith L. Horn 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Diane E. Sullivan 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kostas D. Odysseas 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kostas D. Odysseas 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Louis Sterling III 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Cohen 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrice Bonfiglio 2026-04-18. Form 4, filed 2026-04-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith L. Horn 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kostas D. Odysseas 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Louis Sterling III 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Cohen 2026-04-18. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Berg 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Berg 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aaron Berg 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Provoost 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Provoost 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Ketchum 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jonathan Provoost 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Ketchum 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Keenan 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Keenan 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Keenan 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Steven Ketchum 2026-07-01. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-08-01. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-08-01. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Peter Fishman 2026-08-01. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-15. Item 5.07 · say-on-pay result. As reported: 51.9% (votes for as printed: 87,198,317). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-15. Item 5.07 · say-on-pay result. As reported: 71.09% (votes for as printed: 88,817,073). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-04-22. Item 5.07 · say-on-pay result. As reported: 79.53% (votes for as printed: 111,449,588). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 485,161 + equity 0 + all other 0 = 485,161, summed across the director compensation table rows.
- Harrow, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Harrow, Inc.'s own proxy. As printed: 23,606,274. View filing ↗
- Revance Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2024-03-21. CEO total compensation as printed in Revance Therapeutics Inc.'s own proxy. As printed: 10,068,915. View filing ↗
- Travere Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Travere Therapeutics, Inc.'s own proxy. As printed: 8,457,151. View filing ↗
- Evolus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. View filing ↗
- Innoviva, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-24. CEO total compensation as printed in Innoviva, Inc.'s own proxy. As printed: 5,400,197. View filing ↗
- Xeris Biopharma Holdings Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Xeris Biopharma Holdings Inc.'s own proxy. As printed: 5,042,584. View filing ↗
- Rigel Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals Inc.'s own proxy. As printed: 4,658,805. View filing ↗
- Vanda Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals Inc.'s own proxy. As printed: 3,851,468. View filing ↗
- Amarin Corp PLC\UK (subject), Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Amarin Corp PLC\UK's own proxy. As printed: 3,540,366. View filing ↗
- Esperion Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. View filing ↗
- Heron Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. View filing ↗
- Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
- Coherus BioSciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus BioSciences, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- Karyopharm Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics, Inc.'s own proxy. As printed: 2,320,902. View filing ↗
- MacroGenics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in MacroGenics, Inc.'s own proxy. As printed: 2,078,854. View filing ↗
- Ironwood Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals, Inc.'s own proxy. As printed: 1,948,390. View filing ↗
- Collegium Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
- Section 10a, Vanda Pharmaceuticals Inc. reciprocity. DEF 14A. Vanda Pharmaceuticals Inc. names Amarin Corp PLC\UK in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Innoviva, Inc. reciprocity. DEF 14A. Innoviva, Inc. names Amarin Corp PLC\UK in its own disclosed peer group (read from its most recent proxy). View filing ↗